MarketPulse
I

$IDYA

1 article found
1 positive
0 negative
0 neutral
BenzingaBenzinga··Vandana Singh

IDEAYA's Eye Cancer Drug Combo Demolishes Standard Therapy in Pivotal Trial

$IDYA's darovasertib-crizotinib combination doubled progression-free survival in metastatic uveal melanoma versus standard care, with FDA submission planned for late 2026.
IDYAFDA approvalprogression-free survival